argenx Supportive datasets for Vyvgart in MG and CIDP at AAN
argenx announced the presentation of new data for Vyvgart in MG and CIDP, as well as new data for adimanebart in CMS at the American Academy of Neurology (AAN) conference being held 18-22 April. The presentations include i) New phase 3 ocular MG data for Vyvgart, which shows 2.05-point placebo adjusted MGII PRO improvement, supporting label expansion, ii) post hoc analysis from the ADHERE trial which shows good outcomes in earlier line use, as well as iii) additional pipeline presentations in CIDP (combo trial Vyvgart + empa) and CMS (longer adimanebart follow up). € 900 TP and Buy maintained.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.